A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)
NCT02099123, Phase 4, Active not recruiting, Monash University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) | ClinicalTrials.gov |
| NCT number | NCT02099123 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 9,971 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Monash University | ClinicalTrials.gov |
| Conditions | Independent Living, Disability Free Survival, Elderly, Healthy | ClinicalTrials.gov |
| Interventions | Atorvastatin, Placebo (for Atorvastatin) | ClinicalTrials.gov |
| First posted | 2014-03-28 | ClinicalTrials.gov |
| Last updated | 2024-11-21 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Disability free survival - death or development of dementia or development of persistent physical disability | Time from randomisation to a primary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Defined as survival free of dementia or persistent physical disability (as derived from the endpoints of all-cause mortality, dementia and physical disability) | ClinicalTrials.gov |
| Primary | Major cardiovascular events | Time from randomisation to a primary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Defined as the first occurrence of a cardiovascular death or a non-fatal myocardial infarction or stroke or coronary revascularisation | ClinicalTrials.gov |
| Secondary | A composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | A composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke | ClinicalTrials.gov |
| Secondary | Cardiovascular death | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Fatal cardiovascular events | ClinicalTrials.gov |
| Secondary | Fatal and Non-fatal Mycocardial infarction | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Fatal and non-fatal | ClinicalTrials.gov |
| Secondary | Hospitalisations | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Hospitalisation reasons and length of stay | ClinicalTrials.gov |
| Secondary | Fatal and Non-fatal Cancer | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Fatal and Non-fatal Cancer (excluding non-melanoma skin cancer) | ClinicalTrials.gov |
| Secondary | Other cognitive impairment | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Cognitive decline as assessed using cognitive tests excluding depression | ClinicalTrials.gov |
| Secondary | Quality of life measured by the Short Form Health Survey (SF-36) | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Quality of life (measured by the Short Form Health Survey (SF-36) administered at every second year of follow-up). | ClinicalTrials.gov |
| Secondary | Cost-effectiveness of statin | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Cost-effectiveness of statin | ClinicalTrials.gov |
| Secondary | Fatal and Non-fatal Stroke | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Fatal and Non-fatal Stroke can be a) haemorrhagic or b) thromboembolic | ClinicalTrials.gov |
| Secondary | Approved need for permanent residential care | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | ACAS report | ClinicalTrials.gov |
| Secondary | Dementia | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | All-cause dementia (COWAT, Stroop test, Trail Making Test, HVLT-R, SDMT, ADAS-Cog, Lurian overlapping figures) or external diagnosis | ClinicalTrials.gov |
| Secondary | Persistent physical disability | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | KATZ-ADL administered every 6 months or external diagnosis | ClinicalTrials.gov |
| Secondary | All cause death | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | All cause death | ClinicalTrials.gov |
| Secondary | Heart failure | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Heart failure | ClinicalTrials.gov |
| Secondary | Atrial fibrillation | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Atrial fibrillation | ClinicalTrials.gov |
| Secondary | Revascularisation procedure | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | Revascularisation procedure including coronary revascularisation | ClinicalTrials.gov |
| Other | New onset diabetes | Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years. | New diagnosis of diabetes | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)